News

TALAPRO-2 Trial Supports rPFS as Surrogate for Survival in Advanced Prostate Cancer

Treatment /

The phase 3 TALAPRO-2 trial found that radiographic progression-free survival (rPFS) strongly correlates with overall survival (OS) in first-line metastatic castration-resistant prostate cancer (mCRPC) treated with talazoparib plus enzalutamide. The study analyzed 805 patients in the overall population, 399 with homologous recombination repair (HRR) gene mutations, and 155 with BRCA1/2 alterations. Researchers reported moderate-to-strong correlations […]

TALAPRO-2 Trial Supports rPFS as Surrogate for Survival in Advanced Prostate Cancer Read More »

Disulfiram–Copper Combination Shows Promise in Overcoming Chemotherapy Resistance in Pancreatic Cancer

Research Advances /

Researchers have found that a repurposed drug combination of disulfiram and copper may help overcome chemotherapy resistance in pancreatic cancer, one of the most lethal cancer types. The study focuses on pancreatic ductal adenocarcinoma, where resistance to the chemotherapy drug 5-fluorouracil (5-FU) often limits the effectiveness of standard treatment regimens like FOLFIRINOX. Scientists discovered that

Disulfiram–Copper Combination Shows Promise in Overcoming Chemotherapy Resistance in Pancreatic Cancer Read More »

Nanoparticle Therapy Triggers Immune-Boosting Cancer Cell Death in Pancreatic Tumors

Research Advances /

Researchers are developing a new nanotechnology-based treatment strategy for pancreatic cancer that aims to overcome two major barriers: the tumor’s dense protective tissue and its ability to suppress the immune system. The approach uses smart nanomaterials designed to trigger a form of cancer cell death called ferroptosis, which depends on iron and causes toxic damage

Nanoparticle Therapy Triggers Immune-Boosting Cancer Cell Death in Pancreatic Tumors Read More »

Preoperative Mitomycin-C Before TURBT Reduces Bladder Cancer Recurrence and Progression in 5-Year Study

Clinical Trails /

A Phase 2 randomized study found that giving two preoperative doses of intravesical mitomycin-C before TURBT significantly reduced recurrence and progression in patients with non–muscle-invasive bladder cancer. The strategy is based on the idea that tumor manipulation during surgery can release cancer cells that later reimplant in the bladder. By administering chemotherapy before surgery, while

Preoperative Mitomycin-C Before TURBT Reduces Bladder Cancer Recurrence and Progression in 5-Year Study Read More »

Pembrolizumab Plus BCG Shows High Response Rates in High-Risk Bladder Cancer

Treatment /

A Phase 2 study showed that combining Keytruda with BCG therapy achieved strong responses in patients with very high-risk, BCG-naive non–muscle-invasive bladder cancer. Among 37 patients, 92% achieved a clinical complete response at six months, and no patients progressed to muscle-invasive or metastatic disease during follow-up. The 12-month high-grade recurrence-free survival rate was about 88%,

Pembrolizumab Plus BCG Shows High Response Rates in High-Risk Bladder Cancer Read More »

FDA Approves ctDNA-Guided Tecentriq for Muscle-Invasive Bladder Cancer

Drug Approvals /

The U.S. Food and Drug Administration has approved Tecentriq and Tecentriq Hybreza as adjuvant treatments for patients with muscle-invasive bladder cancer who test positive for circulating tumor DNA (ctDNA) after bladder removal surgery. The approval is tied to the Signatera CDx companion diagnostic, marking a major step toward precision oncology. The decision was based on

FDA Approves ctDNA-Guided Tecentriq for Muscle-Invasive Bladder Cancer Read More »

Phase 2 LEGEND Trial Shows Promise for Gene Therapy in High-Risk Bladder Cancer

Clinical Trails /

Interim results showed that detalimogene voraplasmid, a non-viral intravesical gene therapy, demonstrated encouraging activity and safety in patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer who had already received extensive prior treatment. Among 125 evaluable patients, 54% achieved a complete response at some point during treatment, and most responses were seen by the first two-month assessment.

Phase 2 LEGEND Trial Shows Promise for Gene Therapy in High-Risk Bladder Cancer Read More »

Vitamin B2 Found to Help Cancer Cells Resist Cell Death

Research Advances /

Researchers have discovered that vitamin B2, also known as riboflavin, helps cancer cells survive by protecting them from ferroptosis, a type of cell death caused by iron-driven oxidative damage. The study, published in Nature Cell Biology, found that vitamin B2 supports a protein called FSP1, which strengthens the antioxidant defenses of tumor cells and prevents

Vitamin B2 Found to Help Cancer Cells Resist Cell Death Read More »

Study Identifies Metabolic–Epigenetic Pathway Driving Ovarian Cancer Growth and Suggests New Targeted Therapy

Research Advances /

A study published in Communications Biology has identified pyruvate carboxylase (PC) as a key driver of metabolic changes in epithelial ovarian cancer. Researchers found that high PC levels are linked to more advanced disease, metastasis, recurrence, and poorer survival. The study shows that PC helps cancer cells build up fats by boosting the production of triglycerides

Study Identifies Metabolic–Epigenetic Pathway Driving Ovarian Cancer Growth and Suggests New Targeted Therapy Read More »

FDA Approves All-Oral Inqovi and Venetoclax Combination for Older Patients With AML

Drug Approvals /

On May 13, 2026, the FDA approved an all-oral combination of decitabine/cedazuridine (Inqovi) and venetoclax (Venclexta) for adults with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older or unable to receive intensive chemotherapy. The approval was based on results from the phase 2 ASCERTAIN-V trial involving 101 patients. The study showed

FDA Approves All-Oral Inqovi and Venetoclax Combination for Older Patients With AML Read More »